Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
New Melocules

1421373-65-0 AZD9291 Osimertinib

1421373-65-0 AZD9291 Osimertinib

Osimertinib (previously known as mereletinib and AZD9291; trade name Tagrisso) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug] developed by AstraZeneca Pharmaceuticals - for mutated EGFR cancers.

Disclaimer:Those products (1421373-65-0 AZD9291 Osimertinib) patented are for lab analytical & research purposes only.